Breathe最新文献_第2页

The use of mechanical ventilation in interstitial lung disease. 机械通气在间质性肺疾病中的应用。

IF 2.3

Breathe Pub Date : 2025-04-17 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0172-2024

Timothy J Nolan, Isabel Dwyer, Pierce Geoghegan

引用次数: 0

A case of pulmonary and cutaneous sarcoidosis. 肺及皮肤结节病1例。

IF 2.3

Breathe Pub Date : 2025-04-17 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0228-2024

Eimear Foley, Ahmad Basirat, Ankit Yadav, Shane O'Brien, Patrick D Mitchell, Seamas C Donnelly

引用次数: 0

A non-resolving cough in a 41-year-old woman: a case of familial pulmonary fibrosis. 41岁妇女止咳不愈：家族性肺纤维化1例。

IF 2.3

Breathe Pub Date : 2025-04-17 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0258-2024

Aoife Carolan, Mari Ozaki, Wan Lin Ng, John Ryan, Michael W O'Reilly, Ruth Dunne, Aurelie Fabre, Nadia Nathan, Caroline Kannengiesser, Raphael Borie, Killian Hurley

引用次数: 0

Recurrent unilateral pleural effusion in a 63-year-old man: the answer lies in the mediastinum. 63岁男性复发性单侧胸腔积液：答案在于纵隔。

IF 2.3

Breathe Pub Date : 2025-04-17 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0237-2024

Lorenzo Carriera, Guido Levi, Federico Cremonesi, Giulia Gri, Venere Piluso, Maroon Salameh, Iacopo Ghini, Luisa Lorenzi, Gianpietro Marchetti, Damiano Bottone

引用次数: 0

Cough in idiopathic pulmonary fibrosis: what is new. 特发性肺纤维化的咳嗽：什么是新的。

IF 2.3

Breathe Pub Date : 2025-04-17 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0176-2024

Marta Alexandra Carvalho da Silva, Rui Miguel Mouro de Santos Rolo, Maria Joana Pereira Catarata, Eva Filipa de Sousa Antunes Dias Padrão

{"title":"Cough in idiopathic pulmonary fibrosis: what is new.","authors":"Marta Alexandra Carvalho da Silva, Rui Miguel Mouro de Santos Rolo, Maria Joana Pereira Catarata, Eva Filipa de Sousa Antunes Dias Padrão","doi":"10.1183/20734735.0176-2024","DOIUrl":"https://doi.org/10.1183/20734735.0176-2024","url":null,"abstract":"Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal interstitial fibrosing disease and, despite some well-known risk factors, its cause is still unknown. Cough is experienced by most patients and is commonly chronic and refractory, having a significant impact on quality of life. Its aetiology is complex, combining factors related to interstitial lung disease (ILD) such as an increased sensitivity of cough-sensitive nerves, structural lung changes and inflammation, genetic factors, several comorbidities and medication-adverse effects. Despite the therapeutic advancements in IPF over the past decade with the introduction of antifibrotic drugs that slow disease progression, effective treatment options for cough in IPF remain unavailable. Cough management often relies on empirical approaches based on studies involving chronic cough patients of unspecified causes and ILD physicians' personal experiences. Different classes of medications have been tried over time and, more recently, the focus has turned to neuromodulators and opioids, but several studies have shown suboptimal efficacy in cough. On the other hand, these drugs are associated with significant physical, psychological and economic burdens. However, the future brings us hope to the extent that most current ongoing clinical trials are using new molecules and some have demonstrated promising antitussive effects. This review aims to provide a practical guide to understanding and managing cough in IPF patients, presenting pharmacological and non-pharmacological approaches over time, as well as those treatments that are currently being investigated in clinical settings.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"21 2","pages":"240176"},"PeriodicalIF":2.3,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12004257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thoracic ultrasound in interstitial lung disease. 肺间质性疾病的胸部超声诊断。

IF 2.3

Breathe Pub Date : 2025-04-17 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0170-2024

Dishant Joy Shah, Anthony Esposito, Areen Pitaktong, Harald Sauthoff

引用次数: 0

"Regression to the truth": lessons learned from negative IPF trials. “回归真相”：从负面IPF试验中吸取的教训。

IF 2.3

Breathe Pub Date : 2025-04-17 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0260-2024

Athina Trachalaki, Anna L Lindahl, Simone Petrarulo, George A Margaritopoulos

{"title":"\"Regression to the truth\": lessons learned from negative IPF trials.","authors":"Athina Trachalaki, Anna L Lindahl, Simone Petrarulo, George A Margaritopoulos","doi":"10.1183/20734735.0260-2024","DOIUrl":"https://doi.org/10.1183/20734735.0260-2024","url":null,"abstract":"Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with limited treatment options. Despite the approval of pirfenidone and nintedanib that slow disease progression, IPF remains a disease with poor survival. Promising therapeutic candidates were tested as potential treatments for IPF and while some drugs were successful in phase II clinical trials, their successful transition to positive phase III was unfortunately disappointing. This highlights the \"regression to the truth\" concept in drug development, whereby positive phase II trial results may simply be a statistical anomaly rather than the result of true efficacy. We examine three pivotal trials of novel IPF therapies, zinpentraxin alfa, ziritaxestat and pamrevlumab, that failed in late-stage clinical development. These failures underscore common pitfalls in IPF drug development, including inadequate phase II sample sizes, reliance on surrogate endpoints like forced vital capacity, and challenges integrating background antifibrotic therapies. Moving forward, innovative approaches like adaptive trial designs, Bayesian statistics and composite endpoints could improve trial robustness. Moreover, platform trials may accelerate drug development by testing multiple therapies simultaneously. Negative trials are not failures but opportunities for learning. By recognising and addressing these challenges, while also embracing novel trial methodologies, we can enhance drug development and improve IPF outcomes.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"21 2","pages":"240260"},"PeriodicalIF":2.3,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12004256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From images to clinical insights: an educational review on radiomics in lung diseases. 从影像到临床洞察：肺部疾病放射组学的教育综述。

IF 2.3

Breathe Pub Date : 2025-03-18 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0225-2023

Cheryl Y Magnin, David Lauer, Michael Ammeter, Janine Gote-Schniering

引用次数: 0

The importance of getting the dose right in the treatment of tuberculosis. 正确的剂量在结核病治疗中的重要性。

IF 2.3

Breathe Pub Date : 2025-03-18 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0177-2024

Andrii Dudnyk, Wandini Lutchmun, Raquel Duarte, Christoph Lange, Elin M Svensson

引用次数: 0

Assessment of breathlessness: a pulmonologist's perspective - short of breath, but not short of answers. 评估呼吸困难：肺科医生的观点-呼吸急促，但不缺乏答案。

IF 2.3

Breathe Pub Date : 2025-03-18 eCollection Date: 2025-01-01 DOI: 10.1183/20734735.0096-2024

Ruaidhrí Keane, Vincent Brennan

{"title":"Assessment of breathlessness: a pulmonologist's perspective - short of breath, but not short of answers.","authors":"Ruaidhrí Keane, Vincent Brennan","doi":"10.1183/20734735.0096-2024","DOIUrl":"10.1183/20734735.0096-2024","url":null,"abstract":"Breathlessness, or dyspnoea, is a complex symptom influenced by respiratory, cardiovascular and neural mechanisms, necessitating a systematic and tiered approach for accurate diagnosis and effective management. This review presents a structured, three-tier diagnostic framework, comprising history-taking, static testing (such as pulmonary function tests and thoracic imaging), and dynamic testing (e.g., 6-minute walk test and cardiopulmonary exercise testing) for comprehensive assessment. Each tier is designed to progressively investigate and characterise underlying conditions. This framework is specifically tailored for use in an outpatient general respiratory clinic setting, where clinicians evaluate chronic or unexplained dyspnoea in non-acute patients. Literature and guidelines support this approach, highlighting the importance of combining clinical examination, imaging, laboratory testing and dynamic assessments to capture both static and exertional components of dyspnoea. Emphasising a patient-centred approach, this framework aims to improve diagnostic accuracy and guide targeted therapeutic interventions.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"21 1","pages":"240096"},"PeriodicalIF":2.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0